Ryan Marsh

Senior Research Assistant

Please visit the Pure Research Information Portal for further information
Species turnover within cystic fibrosis lung microbiota is indicative of acute pulmonary exacerbation onset, Cuthbertson, L., Hatfield, L., Gavillet, H., Hardman, M., Marsh, R., Rivett, D., van der Gast, C. 13 May 2025, In: Microbiome
WS04.02: Gut microbiota-metabolome relationships across CFTR modulator usage: preliminary findings from the GRAMPUS-CF study, Marsh, R., Cheung, W., Arends, D., Sills, D., Rivett, D., Smyth, A., van der Gast, C. Jun 2025, In: Journal of Cystic Fibrosis
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis, Marsh, R., Dos Santos, C., Yule, A., Dellschaft, N., Hoad, C., Ng, C., Major, G., Smyth, A., Rivett, D., van der Gast, C. 1 Sep 2024, In: Journal of Cystic Fibrosis
Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome, Marsh, R., Dos Santos, C., Hanson, L., Ng, C., Major, G., Smyth, A., Rivett, D., van der Gast, C. 17 Oct 2023, In: Microbiology spectrum
Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis, Marsh, R., Gavillet, H., Hanson, L., Ng, C., Mitchell-Whyte, M., Major, G., Smyth, A., Rivett, D., van der Gast, C. 1 May 2022, In: Journal of Cystic Fibrosis